Maryann Weitz
Registered Nurse · Boston, MANPI 1679297865
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Sanofi at 55.0% of the total. 2025 is the largest year on record at $3,308, 4.6 times the $712 reported in 2023. Among registered nurse clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 82 payments — averaging $60.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$3K
- Johnson & Johnson$333
- AbbVie$180
- Incyte Corporation$171
- Sanofi-aventis U.S. LLC$166
- Karyopharm Therapeutics Inc.$146
- plus $1K from 26 others
What the payments were for
- Consulting fees$2,66253%
- Food & beverage$1,99240%
- Education$3377%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 7 | $2,747 |
| Johnson & Johnson | 7 | $333 |
| AbbVie | 7 | $180 |
| Incyte Corporation | 4 | $171 |
| Sanofi-aventis U.S. LLC | 5 | $166 |
| Karyopharm Therapeutics Inc. | 3 | $146 |
| AstraZeneca | 5 | $137 |
| Lilly USA, LLC | 2 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $115 |
| Merck | 5 | $96 |
| GSK | 3 | $83 |
| Gilead | 3 | $74 |
| Legend Biotech USA Inc. | 4 | $63 |
| Novartis | 3 | $61 |
| Genentech USA, Inc. | 2 | $60 |
| Seagen Inc. | 2 | $53 |
| Bristol Myers Squibb | 2 | $40 |
| ADC Therapeutics America, Inc. | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| CTI Biopharma Corp. | 1 | $25 |
| Syndax Pharmaceuticals, Inc. | 1 | $25 |
| Caris MPI, Inc. | 1 | $25 |
| Amgen | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Beone Medicines USA, Inc. | 1 | $23 |
| Genmab U.S., Inc. | 1 | $21 |
| Geron Corporation | 1 | $20 |
| Novocure Inc. | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Rigel Pharmaceuticals, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Servier Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,991 in reported general payments places this provider in the 95th percentile of 124 registered nurse providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 75 | $1,255,509 |
| PomalystPomalidomide | 38 | $797,321 |
| NinlaroIxazomib Citrate | 44 | $521,454 |
| ImbruvicaIbrutinib | 15 | $273,575 |
| BrukinsaZanubrutinib | 17 | $152,724 |
| OxycontinOxycodone Hcl | 13 | $16,928 |
| Acyclovir | 65 | $1,475 |
| Duloxetine Hcl | 17 | $390 |
| Pantoprazole Sodium | 25 | $323 |
| Potassium Chloride | 19 | $198 |
| Dexamethasone | 27 | $197 |
| Oxycodone Hcl | 15 | $174 |
| Omeprazole | 12 | $108 |
| Pregabalin | 12 | $79 |
| Gabapentin | 28 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $40 | $1,255,50975 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $115 | $521,45444 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 124 registered nurse providers in Massachusetts.
Other registered nurse in Boston
- Alison MassedBoston$1K
- Anne PlunkettBoston$465
- Raphaela Silva CouzziBoston$433
- Mary CushingBoston$333
- Yun ZhangBoston$247
- Ellen McKeon-LevineBoston$199
- Charlette JallowBoston$187
- Shannon ComeauBoston$184
- Samantha LyBoston$168
- Cornelia PhotopoulosBoston$125
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.